ArticleAnnals of hematology2025
Global burden of acute lymphoblastic leukemia following the COVID-19 pandemic.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07515313 (Expression of CD274), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Expression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by Flowcyometry
Who cites it
1 citing paper in PubMed.
- Proteomic Profiling of Bone Marrow Aspirates from Patients with Methotrexate- and Vincristine-Resistant B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveALL is the most common childhood cancer globally, accounting for about 25% of cancer diagnoses in children under 15 years old. This study aimed to investigate the temporal trends and disparities in the global burden of ALL following the COVID-19 pandemic using data from the Global Burden of Disease (GBD) 2021 study.
methodsData were obtained from the GBD 2021 database, covering 204 countries and territories across five socio-demographic index (SDI) regions. Incidence, prevalence, mortality, and disability-adjusted life years (DALYs) were analyzed, with age-standardized rates (ASRs) calculated for comparability. Joinpoint regression models and estimated annual percentage change (EAPC) were used to assess temporal trends from 1990 to 2021.
resultsGlobally, the incidence of ALL increased from 98,149 cases in 1990 to 103,727 cases in 2021, while the prevalence rose from 237,056 to 386,813 cases. However, the age-standardized incidence rate (ASIR) decreased from 1.8 to 1.4 per 100,000 persons (EAPC = -0.64), and the age-standardized prevalence rate (ASPR) increased from 4.1 to 5.4 per 100,000 persons (EAPC = 1.4). Notably, a significant decrease in incidence was observed in high-middle, middle, and high SDI regions During 2019-2021. Deaths and DALYs showed a downward trend, with the age-standardized death rate (ASDR) and age-standardized DALY rate (ASDALYs) decreasing across all SDI quintiles. The highest burden was observed in children under 5 years, with significant disparities between high-middle and middle SDI regions.
conclusionThe study highlights the impact of the COVID-19 pandemic on the global burden of ALL, particularly in high-middle and middle SDI regions. Tailored prevention strategies and improved healthcare access are needed to address disparities and reduce the burden of ALL. Future research should focus on the long-term effects of the pandemic on ALL. Future research should focus on the long-term effects of the pandemic on ALL outcomes and the development of targeted interventions for high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.